<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121809</url>
  </required_header>
  <id_info>
    <org_study_id>LLC-RAET-2009-1</org_study_id>
    <secondary_id>2009-014480-39</secondary_id>
    <nct_id>NCT01121809</nct_id>
  </id_info>
  <brief_title>Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily</brief_title>
  <acronym>RAET</acronym>
  <official_title>Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily (800 mg and 400 mg, Respectively) Compared With Standard Dosing (400 mg and 200 mg/12 h) in Patients With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospitales Universitarios Virgen del Rocío</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: the intracellular concentrations of raltegravir (RAL) and etravirine (ETV)
      administrated as 800 and 400 mg once a day, respectively, are similar to those obtained with
      the standard doses of 400 and 200 mg/12h, respectively.

      Objective: To analyze the plasma and intracellular concentrations of RAL and ETV
      administrated as 800 and 400 mg once daily respectively compared with standard doses of 400
      and 200 mg/12h, respectively, and if they support its once daily administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To analyze the plasma and intracellular concentrations of RAL and ETV
      administrated as 800 and 400 mg once daily respectively compared with standard doses of 400
      and 200 mg/12h, respectively, and if they support its once daily administration.

      Method: Phase IV, prospective, open labelled clinical trial with a planned duration of 24
      weeks in which 16 patients from Hospitales Universitarios Virgen del Rocío will be enrolled.
      A 12 hours pharmacokinetic profile (immediately before and after 1, 2, 3, 4, 6, 8, 10 and 12
      h) will be obtained after a supervised drug intake while taking RAL or ETV bid.
      Afterwards,the patients will take RAL or ETV once a day for 7 - 10 days. Subsequently, a new
      pharmacokinetic profile (predose and after 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24 h after a
      supervised drug intake) will be obtained.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in pharmacokinetic parameters (Cmax, Cmin, AUC, t1/2, and Cl), both in plasma and intracellular, of RAL and ETV.</measure>
    <time_frame>baseline and 1 week</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>HIV-1 Infection</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Raltegravir 400 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etravirine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Etravirine 200 mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Changing the dose of raltegravir from 400 mg bid to 800 mg qd</description>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etravirine</intervention_name>
    <description>Changing the dose of etravirine from 200 mg bid to 400 mg qd</description>
    <arm_group_label>Etravirine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult HIV-1-infected patients taking raltegravir- or etravirine-based antiretroviral
             regimens

        Exclusion Criteria:

          -  Pregnancy

          -  Concomitant use of drugs that have potential interactions with raltegravir or
             etravirine pharmacokinetics

          -  Cirrhosis with clinical or analytic data of liver failure.

          -  Clinical history suggesting malabsorption or presence of diarrhea (&gt; 3 stools / day)
             that could interfere with the absorption of study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis F Lopez-Cortes, ND, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospitales Universitarios Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>February 7, 2011</last_update_submitted>
  <last_update_submitted_qc>February 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Luis Fernando Lopez-Cortes</name_title>
    <organization>Hospitales Universitarios Virgen del Rocío</organization>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>etravirine</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>intracellular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

